Neurologic manifestations of E coli infection-induced hemolytic-uremic syndrome in adults

Neurology

Volumn 79, Issue 14, 2012, Pages 1466-1473

  Weissenborn, Karin ^a   Donnerstag, Frank ^a   Kielstein, Jan T ^a   Heeren, Meike ^a   Worthmann, Hans ^a   Hecker, Hartmut ^a   Schmitt, Roland ^a   Schiffer, Mario ^a   Pasedag, Thomas ^a   Schuppner, Ramona ^a   Tryc, Anita B ^a   Raab, Peter ^a   Hartmann, Hans ^a   Ding, Xiaoqi Q ^a   Hafer, Carsten ^a   Menne, Jan ^a   Schmidt, Bernhard M W ^a   Bültmann, Eva ^a   Haller, Hermann ^a   Dengler, Reinhard ^a   Lanfermann, Heinrich ^a   Giesemann, Anja M ^a   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN INFECTION; BRAIN STEM; CONSCIOUSNESS DISORDER; CORPUS CALLOSUM; DIFFUSION WEIGHTED IMAGING; DIPLOPIA; ELECTROENCEPHALOGRAM; ESCHERICHIA COLI INFECTION; FEMALE; GLASGOW COMA SCALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERREFLEXIA; MAJOR CLINICAL STUDY; MALE; MESENCEPHALON; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SPEECH DISORDER; THALAMUS; WHITE MATTER;

EID: 84867548399     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31826d5f26     Document Type: Article

References (34)

1. Frank C, Werber D, Cramer JP, et al. Epidemic profile of shiga-toxin: Producing Escherichia coli O104:H4 outbreak in Germany: Preliminary report. N Engl J Med 2011;365: 1771-1780.
2. Abschlieende Darstellung und Bewertung der epidemiologischen Erkenntnisse im EHEC O104:H4 Ausbruch. Deutschland 2011. Available at: Http://www.rki.de/ cln-117/nn-205760/DE/Content/InfAZ/E/EHEC/EHECAbschlussbericht, templateId-raw,property-publication File.pdf/EHEC-Abschlussbericht.pdf. Accessed August 21, 2012.
3. Pennington H. Escherichia coli O157. Lancet 2010;376: 1428-1435.
4. Tarr PI. Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Distinct mechanisms of pathogenesis. Kidney Int Suppl 2009; 112:S29-S32.
5. Hickey CA, Beattie TJ, Cowieson J, et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011;165:884-889.
6. Hahn JS, Havens PL, Higgins JJ, O'Rourke PP, Estroff JA, Strand R. Neurological complications of hemolytic-uremic syndrome. J Child Neurol 1989;4:108-113.
7. Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr 1994;125:511-518.
8. Gianviti A, Tozzi AE, De Petris L, et al. Risk factors for poor renal prognosis in children with haemolytic uremic syndrome. Pediatr Nephrol 2003;18:1229-1235.
9. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008;23:1749-1760.
10. Upadhyaya K, Barwick K, Fishaut M, Kashgarian M, Siegel NJ. The importance of nonrenal involvement in hemolytic-uremic syndrome. Pediatrics 1980;65:115-120.
11. Dücker C, Dautel P, Wagner K, et al. Klinische Symptomatik, Therapie und Verlauf stationär behandelter EHEC/ EHEC-HUS Patienten (clinical symptoms, treatment and outcome of EHEC and EHEC-HUS patients treated as inpatients). Dtsch med Wochenschr 2011;136:1770-1776.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
13. Teasdale G, Jennett B. Assessment of Coma and impaired consciousness. Lancet 1974;304:81-84.
14. Schrezenmeier H, Höchsmann B. Drugs that inhibit complement. Transfus Apher Sci 2012;46:87-92.
15. Greinacher A, Friesecke S, Abel P, et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: A prospective trial. Lancet 2011;378:1166-1173.
16. van Swieten J, Koudstaal P, Visser M, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
17. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of haemolytic uraemic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000;342:1930-1936.
18. Bielaszewska M, Mellmann A, Zhang W, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: A microbiological study. Lancet Infect Dis 2011;11:671-676.
19. Fuller CA, Pellino CA, Flagler MJ, Strasser JE, Weiss AA. Shiga toxin subtypes display dramatic differences in potency. Infect Immun 2011;79:1329-1337.
20. Liman TG, Bohner G, Heuschmann PU, et al. The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: The retrospective Berlin PRES study. J Neurol Epub 2011 Jun 30.
21. Bennett B, Booth T, Quan A. Late onset seizures, hemiparesis and blindness in hemolytic uremic syndrome. Clin Nephrol 2003;59:196-200.
22. Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2010;5:1218-1228.
23. Ahrens F, Ludwig K, Terstegge K, Querfeld U. Encephalopathy and exposure to Shiga toxin without evidence of haemolytic uremic syndrome. Eur J Pediatr 2002;161: 462-463.
24. Obata F. Influence of Escherichia coli shiga toxin on the mammalian central nervous system. Adv Appl Microbiol 2010;71:1-19.
25. Obata F, Tohyama K, Bonev AD, et al. Shiga toxin 2 affects the central nervous system through receptor globotriaosylceramide localized to neurons. J Infect Dis 2008; 198:1398-1406.
26. Bauwens A, Bielaszewska B, Kemper B, et al. Differential cytotoxic actions of Shiga toxin 1 and Shiga toxin 2 on microvascular and macrovascular endothelial cells. Thromb Haemost 2011;105:515-528.
27. Louise CB, Obrig TG. Shiga toxin-associated hemolyticuremic syndrome: Combined cytotoxic effects of Shiga toxin, interleukin-1, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect Immun 1991;59:4173-4179.
28. Van Setten PA, van Hinsbergh VWM, van der Velden TJAM, et al. Effects of TNF- on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 1997;51:1245-1256.
29. Ramegowda R, Samuel JE, Tesh VL. Interaction of Shiga toxins with human brain microvascular endothelial cells: Cytokines as sensitizing agents. J Infect Dis 1999;180: 1205-1213.
30. Eisenhauer PB, Chaturvedi P, Fine RE, et al. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect Immun 2001;69:1889-1894.
31. Tironi-Farinati C, Loidl CF, Boccoli J, Parma Y, Fernandez-Miyakawa ME, Goldstein J. Intracerebroventricular Shiga toxin 2 increases the expression of its receptor globotriaosylceramide and causes dendritic abnormalities. J Neuroimmunol 2010;222:48-61.
32. Goldstein J, Loidl CF, Creydt VP, Boccoli J, Ibarra C. Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: An ultrastructural study. Brain Res 2007;1161:106-115.
33. Teramoto T, Fukao T, Hirayama K, Asano T, Aoki Y, Kondo N. Escherichia coli O-157-induced hemolytic uremic syndrome: Usefulness of SCWP score for the prediction of neurological complication. Pediatr Int 2009;51: 107-109.
34. Harrison LM, Cherla RP, van den Hoogen C, van Haaften WC, Lee SY, Tesh VL. Comparative evaluation of apoptosis induced by Shiga toxin 1 and/or lipopolysaccharides in human monocytic and macrophage-like cells. Microbiol Pathogenesis 2005;38:63-76.